-transparent.png){kind=logo}
Adenosine deaminase (ADA) and the HIV-1 transactivator protein Tat have been reported to bind to human CD26, also known as dipeptidyl peptidase IV (DPP IV). In order to demonstrate the specificity of such binding under native conditions of CD26, i.e., when expressed on the cell surface, we established murine cell lines expressing transfected human CD26, either wild-type or mutated at its serine-630, which inactivates the DPP IV activity. This experimental system is advantageous since murine ADA does not bind human CD26, whereas human and bovine ADA bind. Consequently, murine cell clones expressing either the wild-type or mutated form of human CD26 were found to bind specifically bovine 125I-labeled ADA with a high affinity (KD = 12 +/- 2 nM and 11 +/- 4 nM, respectively). No specific binding of 125I-labeled ADA was observed to murine clones not expressing human CD26. The binding of 125I-labeled ADA to CD26 was further characterized by the use of monoclonal antibodies specific to human CD26. The results obtained were in accord with those reported previously using other experimental models. These observations indicated that the murine cells expressing human CD26 provide a highly suitable model to investigate the potential binding of HIV-1 Tat to CD26. In contrast to previously published results, however, we could not demonstrate a specific interaction between Tat and human CD26. The 125I-labeled ADA-specific binding to human CD26 was not affected by Tat, even at concentrations which induced cell death. Similarly, the binding of several monoclonal antibodies to human CD26 was not modified by the addition of Tat. More significantly, Tat binding to different murine cell clones (human CD26 negative or positive) was found not to be correlated with the expression of human CD26. Finally, the toxic effect of Tat on the growth of different murine cell clones was independent of human CD26 expression. Taken together, these observations further confirm the specific binding of ADA to human CD26 and point out that CD26 is not the target of HIV-1 Tat protein.
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
January 1997,
Advances in experimental medicine and biology,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
April 1997,
Journal of immunology (Baltimore, Md. : 1950),
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
November 2000,
The Journal of experimental medicine,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
May 2003,
Neurochemistry international,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
December 2003,
IUBMB life,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
March 1994,
European journal of immunology,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
November 1998,
Proceedings of the National Academy of Sciences of the United States of America,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
June 1997,
Cellular immunology,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
October 1979,
Biochimica et biophysica acta,
J Blanco, and
I Marié, and
C Callebaut, and
E Jacotot, and
B Krust, and
A G Hovanessian
July 1994,
Genomics,
